Black Swan Analysis Blog
In this article, Christopher Ehinger questions whether rare diseases are a viable option for the pharma industry. He looks at the total number of approvals and orphan drug designations in the US...
Christopher Ehinger of Black Swan Analysis explores one of the key trends in the pharma industry at the moment: defining patient populations. He believes that in order to be successful in the...
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem.
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharma forecasting.
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast
*In the run up to Forecasting Europe  in Berlin in June, eyeforpharma asked some of our key speakers for their ins*  http://www.eyeforpharma.com/forecastingeu/
Peter Mansell explores how pharmaceutical forecasters are developing new methods and new metrics to enable them to make better guesses